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Abstract
Background: Glyoxalase I is a metalloenzyme of the glyoxalase pathway that plays a central role in eliminating the toxic
metabolite methyglyoxal. The protozoan parasite Leishmania donovani possesses a unique trypanothione dependent
glyoxalase system.
Principal Findings: Analysis of the L. donovani GLOI sequence predicted a mitochondrial targeting sequence, suggesting
that the enzyme is likely to be targeted to the mitochondria. In order to determine definitively the intracellular localization
of GLOI in L. donovani, a full-length GLOI gene was fused to green fluorescent protein (GFP) gene to generate a chimeric
construct. Confocal microscopy of L. donovani promastigotes carrying this chimeric construct and immunofluorescence
microscopy using anti-GLOI antibodies demonstrated that GLOI is localized in the kinetoplast of the parasite apart from the
cytosol. To study the physiological role of GLOI in Leishmania, we first created promastigote mutants heterozygous for GLOI
by targeted gene replacement using either hygromycin or neomycin phosphotransferases as selectable markers.
Heterozygous mutants of L. donovani display a slower growth rate, have lower glyoxalase I activity and have reduced ability
to detoxify methylglyoxal in comparison to the wild-type parasites. Complementation of the heterozygous mutant with an
episomal GLOI construct showed the restoration of heterozygous mutant phenotype nearly fully to that of the wild-type.
Null mutants were obtained only after GLOI was expressed from an episome in heterozygous mutants.
Conclusions: We for the first time report localization of GLOI in L. donovani in the kinetoplast. To study the physiological
role of GLOI in Leishmania, we have generated GLOI attenuated strains by targeted gene replacement and report that GLOI
is likely to be an important gene since GLOI mutants in L. donovani showed altered phenotype. The present data supports
that the GLOI plays an essential role in the survival of this pathogenic organism and that inhibition of the enzyme
potentiates the toxicity of methylglyoxal.
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Introduction
Leishmaniasis constitutes a wide spectrum of diseases ranging
from the simple self-limiting cutaneous form to the debilitating
visceral form, which is often fatal if left untreated. The protozoan
parasite Leishmania donovani is the major causative agent of visceral
leishmaniasis. The current challenges in its chemotherapy include
widespread resistance to pentavalent antimony; absence of safe
and cost-effective antileishmanial agents and relapses in HIV
Leishmania co-infected patients. Thus an urgent need exists to look
for newer and more effective drug targets to treat leishmaniasis.
The glyoxalase system of Leishmania is one such pathway that
may be exploited successfully for the development of anti-parasitic
drugs. The glyoxalase system is a ubiquitous thiol-dependent
detoxification pathway [1]. This system comprises of two enzymes,
glyoxalase I (GLOI) (lactoylglutathione lyase, EC 4.4.1.5) and
glyoxalase II (GLOII) (hydroxyacylglutathione hydrolase, EC
3.1.2.6). Glyoxalase I catalyses the formation of S-D lactoyl
glutathione from the hemithioacetal formed nonenzymatically
from methylglyoxal and glutathione. Glyoxalase II converts S-D
lactoyl glutathione to lactate and free glutathione [2]. Recent
reports demonstrated a unique glyoxalase system in pathogenic
kinetoplastids, as a consequence of this protozoan possessing an
unusual thiol metabolism [3,4,5]. Glyoxalase I and glyoxalase II in
kinetoplastids showed high level of specificity to trypanothine
hemithioacetal and little activity with glutathione hemithioacetal
[3,4,5,6]. The unique nature of this trypanothione-dependent
glyoxalase pathway represents a novel chemotherapeutic target for
the kinetoplastids. A major function of the glyoxalase pathway is
believed to be detoxification of a-ketoaldehydes, especially
methylglyoxal (MG). MG is a cytotoxic metabolite produced
primarily as a by-product of glycolysis through nonenzymatic
phosphate elimination from the glycolytic pathway intermediates,
dihydroxyacetone phosphate and glyceraldehyde 3-phosphate [2].
The glyoxalase enzymes have been reported to have a regulatory
role in cell division including cell proliferation, tissue regeneration,
and malignancy besides detoxification of methylglyoxal [7]. We
had earlier cloned and characterized the genes encoding
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glyoxalase I (GLOI) (AY739896) and glyoxalase II (GLOII)
(AY851655) from Leishmania donovani [5,6]. Glyoxalase I is a single
copy gene and is placed at a single chromosomal band of
,2.2 Mb. Multiple sequence alignment and homology modeling
clearly showed that there is a crucial difference in the active site of
human and Leishmania glyoxalase I enzymes suggesting that the
glyoxalase I may be a potential target for drug design [5].
In the present study we report that L. donovani promastigotes
carrying a GLOI-green fluorescent protein (GLOI-GFP) chimeric
construct display localization of GLOI in the kinetoplast of the
parasite apart from the cytosol. To study the physiological role of
GLOI in Leishmania, we have generated GLOI attenuated strains by
targeted gene replacement. Attempts to disrupt both alleles of GLOI
in L. donovani promastigotes resulted in change in levels of cell ploidy.
These GLOI mutants were phenotypically characterized and
showed reduced growth, lower GLOI enzymatic activity and had
reduced ability to detoxify methylglyoxal in comparison to the wild-
type parasites. Null mutants of GLOI were obtained only after
rescuing the heterozygous mutants with an episomal copy of GLOI.
This data suggests that the GLOI is essential to L. donovani.
Results
Subcellular localization of Glyoxalase I in L. donovani
Amino acid sequence analysis of the LdGLOI protein in-silico using
pSORT [8] and MitoProt II [9] web-based programs predicted that
GLOI is localized to the mitochondria with a P=0.8780 probability.
However, no cleavage site was predicted for the mitochondrial
targeting sequence using Target P web based program [10]. To
determine the localization of GLOI in intracellular organelles, we
investigated the localization of a GFP-tagged version of GLOI in L.
donovani and compared with the wild type parasites, transfected with the
vector alone (pGEM-7zfaNeoa-GFP) (Fig. 1A, panel 5 and 6).
Confocal microscopy showed that the GLOI2GFP fusion protein was
localized both in the cytosol and the Leishmania kinetoplast (Fig. 1A,), as
seen by the clear co-localization of the GLOI2GFP with the
fluorescence associated to the MitoTracker Red CMX Ros that
reveals the position of mitochondria within the promastigotes (Fig. 1A,
panel 1, 3 and 4). Immuno-localization of GLOI using anti-GLOI
antibodies and Alexa 546 labeled anti mouse IgG as secondary
antibody in the L.donovani expressing GLOI as GFP translational fusion
Figure 1. Localization of GLOI in L. donovani. A: Panel 1: confocal microscopy of wild type L. donovani transfected with pGEM7zf-aNEOa-GFP-
GLOI expressing GLOI as a GFP translational fusion protein and stained with Mitotracker-Red CMX Ros dye, Panel 2: phase contrast image, Panel 3:
wild type L. donovani expressing GLOI as a GFP translational fusion protein, Panel 4: merged micrograph, Panel 5: wild type L. donovani transfected
with pGEM7zf-aNEOa-GFP vector alone expressing GFP, Panel 6: phase contrast image B: Panel 1: Immunoflourescence analysis by confocal
micrograph of wild type L. donovani parasite transfected with pGEM7zf-aNEOa-GFP-GLOI,using anti–GLOI antibody, Panel 2: phase contrast image.
Panel 3: wild type L. donovani expressing GLOI as a GFP translational fusion protein, 4: merged micrograph C: Panel 1: Immunoflourescence analysis
by confocal micrograph of wild type L. donovani parasite transfected with pGEM7zf-aNEOa-GFP-GLOI using anti-GLOI antibody, Panel 2: wild type L.
donovani expressing GLOI as a GFP translational fusion protein, Panel 3: stained with DAPI, Panel 4: phase contrast image, Panel 5: merged
micrograph. D: Western blotting using anti-GLOI antibody. Cytosolic and mitochondrial fractions were separated from late log phase promastigotes
(16108) expressing GLOI as a GFP translational fusion protein. Lane 1: recombinant GLOI, Lane 2: cytosolic fraction, Lane 3: mitochondrial fraction. The
blot was also probed with mitochondrial specific anti-F1 ATP synthase a-subunit. Results are representative data from three separate experiments.
doi:10.1371/journal.pone.0006805.g001
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protein, further confirmed the presence of GLOI in the kinetoplast and
the cytosol and not in the nucleus (Fig. 1B panel 1, 3 and 4). Immuno-
localization of GLOI using anti-GLOI antibodies and Alexa 546
labeled anti mouse IgG as secondary antibody was also done and
counter stained with DAPI to confirm the position of the nucleus and
the kinetoplast with in the parasites (Fig. 1C, panel 1, 2, 3 and 5).
Western blot analysis with both the cytosolic and mitochondrial
fraction (100 mg protein lysate) of the GLOI-GFP transfected parasites
showed a band of ,44.5 kDa that corresponded to the size of the
fusion protein and a band of 16 kDa that corresponded to the native
L.donovaniGLOI protein. These experiments confirmed the presence of
GLOI with in the kinetoplast and the cytosol of the parasites
(Fig. 1D).The mitochondrial fraction was further confirmed by
reprobing the blot with mitochondrial specific anti-F1 ATP synthase
a-subunit (Fig. 1D).
Construction and Molecular characterization of GLOI
mutants
From our earlier studies it is known that GLOI is a single copy
gene in L. donovani and is placed at a single chromosomal band of
,2.2 Mb [5]. Since Leishmania is considered to be diploid and no
sexual crosses have been achieved, homologous recombination
strategy has been used in an attempt to generate transgenic
parasites lacking both alleles of GLOI. The wild type parasites were
transfected individually with the hyg and neo replacement cassettes
to create the GLOI heterozygotes; Ld GLOI :: HYG (+/h) and Ld
GLOI :: NEO (+/n) respectively (Fig. 2). The Hyg and Neo
transfectants were selected against hygromycin (200 mg/ml) and
G-418 (40 mg/ml) respectively. The representative clone from the
Ld GLOI :: HYG (+/h) and Ld GLOI :: NEO (+/n) single knock out
mutants were screened for the correct integration of the hyg and neo
replacement cassette respectively. The SalI digested genomic DNA
from the wild-type L. donovani and representative L. donovani
heterozygous clones Ld GLOI :: HYG (+/h) and LdGLOI :: NEO (+/
n) were subjected to Southern blot analysis and results are
presented in Fig. 3. The integrations of the selectable markers were
confirmed by hybridization with hyg and neo specific probes. The
hyg specific probe (1026-bp) resulted in no hybridizing bands with
SalI-digested genomic DNA from wild type parasites and Ld
GLOI::NEO (+/n) clones, while a single band of ,6.8 kb,
Figure 2. Schematic representation of the wild type and the hyg, neo and phleo targeted Ld GLOI locus. SalI restriction sites were used to
analyze the recombination events. The restriction fragments obtained after Sal I digestion are indicated by double headed arrows along with their
respective size. Thick arrows indicate the ORF of genes as indicated. Bold arrows indicate the 59 and 39 flanking regions of GLOIORF. Solid bars indicate the
probes used for Southern blot analysis. Primers P 1 and P 2 were used to check the correct integration of hyg cassette and primers P 1 and P 3 were used to
check the correct integration of neo cassette. Restriction sites (H- HindIII, B- BamHI, Bg - BglII, SalI) used for cloning 59 and 39 flank are also indicated.
doi:10.1371/journal.pone.0006805.g002
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corresponding to the hyg based replacement fragment was detected
in L. donovani heterozygous clones, Ld GLOI :: HYG (+/h) (Fig. 3A).
The neo specific probe (800-bp) resulted in no hybridizing band
with SalI digested genomic DNA from the wild-type (+/+)
parasites and representative Ld GLOI :: HYG (+/h) clones but a
single band of ,6.7 kb was detected in the Ld GLOI :: NEO clone
(+/n) (Fig. 3B). Southern blot analysis of SalI-digested genomic
DNA from wild-type parasites (+/+), L. donovani heterozygotes Ld
GLOI :: HYG (+/h), Ld GLO :: NEO (+/n), a double transfectant
mutant clone Ld GLOI :: HYG :: NEO (+/h/n) and a GLOI
complementation mutant (+/h–GLOI+) was performed and blots
were hybridized with the GLOI ORF probe (426 bp). An expected
2.2 kb band was recognized in the DNA from wild-type L. donovani
(+/+) and L. donovani heterozygous mutants Ld GLOI :: HYG clone
(+/h), Ld GLOI::NEO clone (+/n) and GLOI complementation
mutant (+/h –GLOI+). An additional and expected band of
6.7 Kb was observed in the (+/h)-GLOI+ transfectant that
corresponds to the presence of an episomal copy of GLOI in the
Ld GLOI :: HYG (+/h) background. However, the double
transfectant mutant clone, Ld GLOI :: HYG :: NEO (+/h/n)
showed the presence of a GLOI specific band of 2.2 kb (Fig. 3C). A
total of ten double transfectant mutant (+/h/n) clones were
screened and a 2.2 kb specific GLOI band was present in all the
clones (representative data from one clone is shown). Although
GLOI gene disruption by neo and hyg took place, as clearly shown
from the hybridization studies with the hyg (Fig. 3A) and neo probes
(Fig. 3B), one GLOI allele remained intact since the 2.2 kb
genomic SalI fragment was still present in the double targeted
mutants (Fig. 3C, lane: +/h/n). The gene replacement of four of
the (+h/n) clones was further evaluated by polymerase chain
reaction (PCR).
PCR based approach was also used to analyze for the correct
integration of the hyg and neo based replacement constructs.
Integration specific primers P1 and P2 as mentioned in the
material and methods and shown in Fig. 2 were used to determine
hyg specific integration (Fig. 3E), whereas P1 and P3 was used to
verify neo specific integration (Fig. 3F). Southern blotting of the
PCR products of the wild type (+/+), Ld GLOI :: HYG clone (+/h),
Figure 3. Southern blot and PCR analysis of GLOI knockout mutants. Southern blot analysis of wild type and mutant parasites to confirm the
recombination events. Equal amount of genomic DNA (5 mg) was digested with SalI restriction enzyme and separated on a 0.8% agarose gel. The
DNA was blotted on to membrane and hybridized with hyg specific probe (A), NEO specific probe (B), GLOI specific probe (C) and PHLEO specific
probe (D). (+/+) represents Wild type; (+/h) represents heterozygote LdGLOI::HYG clone; (+/n) represents heterozygote LdGLOI :: NEO clone; (+/h/n)
represents L. donovani double targeted transfectant, LdGLOI :: HYG :: NEO clone, (+/h-GLOI+) represents GLOI complementation mutant and (2/2
GLOI+) represents GLOI null mutants rescued with an episomal copy of GLOI.M represents DNA molecular weight marker; uncut pX63-HYG and pX63-
NEO and linearized pGEM7zfaNeoa-GLOI+ plasmids were used as positive controls for the respective blots probed with HYG, NEO and GLOI. PCR was
carried out with primers P1 and P2 for checking hyg cassette integration (E, panel a) and with primers P1 and P3 for checking neo cassette integration
(F, panel a). Southern blot analysis of the corresponding PCR gels probed with HYG (E, panel b) and NEO (F, panel b). G: Southern blot analysis of
genomic DNA digested with SalI and probed with PHLEO probe to verify phleo cassette integration.
doi:10.1371/journal.pone.0006805.g003
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Ld GLOI :: NEO clone (+/n) and double transfectant mutant clone
Ld GLOI::HYG::NEO (+/h/n) using hyg (Fig. 3E, panel b) and neo
(Fig. 3F, panel b) specific probes further confirmed the expected
integration. These observations confirmed the generation of single
knockouts of GLOI by both hyg and neo based replacement
cassettes. PCR studies further confirmed that in the double
transfectant mutant clone Ld GLOI :: HYG :: NEO (+/h/n)
disruption of GLOI gene by neo (Fig. 3F, panel b) and hyg (Fig. 3E,
panel b) took place.
Since the double transfectant mutant clones Ld GLOI::HYG::-
NEO (+/h/n) were found to contain 2.2-kb wild type GLOI allele as
well as hyg and neo integrations, DNA content based analysis was
performed to check the ploidy levels of the cells. This was
determined by fluorescence activated cell sorting (FACS) analysis
of fixed cells stained with propidium iodide (Fig. 4). In the wild
type cells (+/+), two peaks corresponding to 2N (G1) and 4N (G2)
DNA content were observed as expected (Fig. 4 panel A). Similar
pattern was observed with the heterozygote mutants (+/h) and (+/
n) and GLOI complementation mutant (+/h-GLOI+) (Fig. 4.
panels B, C and D) thereby showing that these clones contain
normal diploid DNA content similar to the wild type cells.
However, analysis of the double transfected mutant clone (+/h/n)
showed peaks that corresponded to 3N and ,6N DNA content
(Fig. 4 panel E) (representative data from one of the clones is
shown). This suggests a difference in the ploidy level in the cell
population of the double transfectants when compared to the wild
type cells. The G1 peak of the double transfected mutant clone
indicates that these cells are aneuploid (Fig. 4. panel E).
In order to create null mutant of GLOI, a further attempt was
made to express the gene from an episome prior to disrupting the
second GLOI allele. The heterozygous GLOI mutant with an
episomal copy of GLOI (+/h-GLOI+) was transfected with the
linearized pX63-PHLEO-DGLOI construct. The transfectants
were selected against hygromycin (200 mg/ml), G418 (40 mg/ml)
and phleomycin (25 mg/ml). The null mutants thus obtained were
designated as (2/2GLOI+). The SalI digested genomic DNA
Figure 4. DNA content analysis. Wild type and GLOI mutant L.donovani cell lines were analysed for DNA content using flow cytometry. A: Wild
type (+/+): B: heterozygote LdGLOI :: HYG clone (+/h); C: heterozygote LdGLOI :: NEO clone (+/n);, D: GLOI complementation mutant (+/h-GLOI+); E: L.
donovani double targeted transfectant, LdGLOI :: HYG :: NEO clone (+/h/n) were fixed and stained with propidium iodide and analysed using a Beckton
Dickinson flow cytometer(FACScalibur). Representative peaks of G1 and G2 phase are shown as predicted by the CELL QUEST software. Results are
representative data from three separate experiments.
doi:10.1371/journal.pone.0006805.g004
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from nine clones was subjected to Southern blotting and the blot
was hybridized with GLOI (426-bp) (Fig. 3D) or phleo (375-bp)
specific probe (Fig. 3G). A representative data from two (2/
2GLOI+) clones is shown in Fig. 3D and 3G. The 2.2 kb GLOI
fragment was present in the wild type L. donovani (+/+),
heterozygous mutants, Ld GLOI :: HYG clone (+/h), LdGLOI::NEO
clone (+/n) and GLOI complementation mutant (+/h –GLOI+).
The two mutant clones (2/2GLOI+) lacked 2.2-kb wild type
GLOI fragment. These two clones were found to contain an
intensely hybridizing fragment of 6.7-kb which corresponded to
the presence of an episomal copy of GLOI in the Ld GLOI :: HYG
(+/h) background. These clones were also checked for the correct
integration of the phleo replacement cassette by Southern blot
analysis of SalI digested genomic DNA followed by hybridization
with the phleo probe. Fig. 3G shows that both the clones (2/
2GLOI+) contain 6.1-kb fragment indicative of the correct
integration of the phleo cassette.
A total of at least two clones of each of the mutant lines were
picked and screened for phenotypic characterization. Represen-
tative data from one clone from each mutant line is presented
below.
GLOI heterozygous mutants are growth defective
In order to verify phenotypic alteration in these gene
replacement mutants, the growth rate of each of the cell lines
was determined for a period of 120 h at an interval of 24 h. Fig. 5
shows the growth of the wild-type L. donovani, Ld GLOI :: HYG (+/
h), Ld GLOI :: NEO (+/n) and complementation clone (+/h)-GLOI+
and double targeted transfectant clone Ld GLOI :: HYG :: NEO (+/
h/n). The promastigotes of the GLOI heterozygous mutants (+/h)
and (+/n) showed a slower growth rate when compared to that of
the wild-type cells (+/+). The GLOI heterozygous mutants (+/h)
clone when complemented with an episomal copy of GLOI showed
an increase in the growth rate as compared to the heterozygous
mutant, thereby revealing that the presence of GLOI as an
episomal copy facilitates in overcoming the defect in the growth
that probably has arisen because of the deletion of one of the wild
type GLOI allele. Double targeted transfectant clone (+/h/n) had
growth pattern similar to that of the heterozygous GLOI mutant
strains.
GLO I heterozygous mutants exhibit reduced
methylglyoxal (MG) detoxification
The effective concentration of methylglyoxal (MG) that
inhibited cell growth by 50% (IC50) was 1.060.1 mM in the
wild-type L. donovani. However, that of the L. donovani heterozygous
mutants, Ld GLOI :: HYG (+/h) and Ld GLOI :: NEO (+/n), was
0.4560.03 mM and 0.3060.02 mM. In the case of the double
targeted transfectant clone (+/h/n) the effective concentration was
0.4160.04 (Table 1). This data indicates that L. donovani mutants
probably have a significantly reduced rate of metabolism of MG as
compared to the wild-type parasites suggesting that the glyoxalase
pathway is the dominant route for detoxification of MG in L.
donovani. However, the heterozygous mutant clone Ld GLOI :: HYG
(+/h) when transfected with an episomal copy of GLOI (+/h-
GLOI+) had an IC50 = 0.860.07 mM towards MG. This date
indicates that complementation of GLOI in heterozygous mutant
clone Ld GLOI :: HYG (+/h) decreases the sensitivity towards
methylglyoxal.
Reduction in glyoxalase I activity in GLOI heterozygous
mutant
The specific activity of GLOI in heterozygous mutants, Ld GLOI
:: HYG (+/h) and Ld GLOI :: NEO (+/n), was 173631 nmol -
min21 mg21protein and 116.5633 nmol min21 mg21protein re-
spectively. The specific activity in the double targeted transfectant
clone (+/h/n) was 109.5613 nmol min21 mg21protein. Howev-
er, a higher specific activity of GLOI in the wild-type L. donovani
(486619.8 nmol min21 mg21protein) was observed when com-
pared to the respective mutants. Thus, Glyoxalase I activity in L.
donovani mutants showed an approximately two fold reduction as
compared to the wild-type L. donovani. The heterozygous mutant
Ld GLOI:: HYG (+/h) when complemented with an episomal copy
of GLOI had a specific activity of 345628 nmol min21 mg21-
protein (Table 2).
The rescued null mutant clones (2/2GLOI+) had normal
diploid content. The growth pattern, IC50 towards MG and
specific activity of GLOI null mutant clones (2/2GLOI+) was
similar to that of the GLOI complementation mutant (+/h –
GLOI+) (data not shown).
Discussion
The glyoxalase system, consisting of the enzymes glyoxalase I
(GLOI) and glyoxalase II (GLOII), is an integral component of
cellular metabolism in mammalian systems. Although the
glyoxalase pathway was reported as early as 1913 [11,12] and is
Figure 5. Growth profile of promastigotes of wild type (+/+),
heterozygote LdGLOI :: HYG clone (+/h); heterozygote LdGLOI ::
NEO clone (+/n); L. donovani double targeted transfectant,
LdGLOI :: HYG :: NEO clone (+/h/n), GLOI complementation
mutant (+/h-GLOI+). Growth comparison was done by inoculating
stationary phase cells in modified M199 medium with 10% FBS at a
density of 16106 cells/ml. Cells were counted at 24 h intervals using a
Neubauer hemocytometer. Results are representative data from two
separate experiments with mean6SD of triplicates in each set.
doi:10.1371/journal.pone.0006805.g005
Table 1. Effect of methyglyoxal on the cell viability of the
Wild type and the mutant parasites.
Strain IC506S.D. (mM)
Wild type (+/+) 160.14
Ld GLOI :: hyg (+/h) 0.4560.03*
Ld GLOI :: neo (+/n) 0.360.02*
Ld GLOI hyg :: neo (+/h/n) 0.4160.04*
Ld GLOI :: hyg GLO I +(+/h -GLOI +) 0.860.07
IC50 represents the concentration of methylglyoxal, which inhibited the growth
of the wild type and the mutant parasites by 50%. Each value is a mean6S.D. of
three independent experiments.
*Significantly different from the wild type (P,0.001).
doi:10.1371/journal.pone.0006805.t001
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widely distributed in living organisms, its full biological function
has never been elucidated. A major function of the glyoxalase
pathway is believed to be detoxification of a-ketoaldehydes,
especially methylglyoxal (MG). MG is a cytotoxic metabolite
produced primarily as a by-product of glycolysis [13]. Another role
of GLOI and methylglyoxal is their involvement in the regulation
of cellular growth [14]. In tumor tissues high activities of
glyoxalase I have also been reported [15]. Inhibitors of glyoxalase
I have been reported to be selectively toxic to proliferating cells,
this could be due to increased accumulation of methylglyoxal that
could lead to inhibition of DNA synthesis [16,17]. Glyoxalase I
inhibitors have been reported to have antimalarial [18] and
antitrypanosomal activities [19]. The glyoxalase system of the
pathogenic kinetoplastids has been recently reported to be unique,
as a consequence of these protozoa possessing an unusual thiol
metabolism. In these organisms, instead of glutathione, the major
low molecular mass thiol is trypanothione [N1, N8-bis (glutathio-
nyl) spermidine] [4,5]. It has been recently reported that the
GLOI system in L. major and L. donovani uses trypanothione as the
substitute for glutathione [4,5]. The metal cofactor is zinc in
eukaryotes and nickel in E. coli [20,21] and L. major [4]. Thus both
the substrate and cofactor of Leishmania glyoxalase are different
from the mammalian glyoxalases. The difference in cofactor
dependence is reflected in differences between the active sites of
the human and Leishmania enzymes, suggesting that the latter may
be a target for antimicrobial therapy [22,23].
Localization studies using L. donovani GLOI–GFP translational
fusion shows that GLO I is localized not only in the cytosol of the
parasites but also in the kinetoplast. Analysis of L. donovani GLOI
sequences with MitoProt II [9] suggested targeting of proteins to
the mitochondria. The GLO I enzyme is likely to be exported to
the mitochondria with a P=0.8780. Anlaysis of the L. donovani
GLOI sequences with PSORT also suggested it to be a
mitochondrial protein. This observation is supported from the
sequence analysis of T. cruzi and L. major GLOI with MitoProt II
having a P= 0.909 and 0.8704 respectively [24].
The biological function of a gene in an organism can be
assessed by generating a knockout line and then characterizing
the phenotype of the mutant. The functions of several genes of
Leishmania have been established using gene targeting procedures
[25,26,27,28]. Our earlier studies have shown that the GLOI is a
single copy gene and the expression is highest in late log phase
promastigotes [5]. Homologous recombination strategy has
been used to obtain single knock out mutants Ld GloI :: HYG
(+/h) and Ld GLOI :: NEO mutants (+/n). Both these mutants
exhibited slow growth rate and decrease in the specific activity of
the glyoxalase I enzyme when compared to the wild-type. The
decrease in enzymatic activity probably causes accumulation of
MG derived adducts and induces oxidative stress in the mutants.
Loss of one GLOI allele by gene disruption was compensated by
genetic complementation with an episomal copy of GLOI. Our
attempts to generate GLOI null mutants by step wise gene
replacement failed despite the successful disruption of the two
alleles by gene targeting. Earlier reports show that in L. major,
generation of dihydrofolate reductase-thymidylate synthase null
mutant [29] resulted in an increase in the chromosome number
in order to keep one dhfr-ts allele intact. Similarly disruption of
the trypanothione reductase (TR) gene of Leishmania led to
partial trisomy for the TR locus [30]. It has been proposed that
such alteration in the genome could be an indicator of the
essential nature of the gene. In order to address this problem in
the present study, the DNA content of the mutant lines was
determined by FACS analysis and compared to that of the wild
type. A normal diploid DNA content was observed in the wild
type, heterozygous mutants with hyg replacement cassette (+/h),
heterozygous mutant with neo replacement cassette (+/n), and
GLOI complementation mutant (+/h-GLOI+). However, anal-
ysis of the DNA content of the double targeted transfectant (+/
h/n) indicated that the second round of gene replacement
resulted in aneuploidy. This change in ploidy has occurred
during the introduction of the second replacement construct.
The mechanism by which such changes in ploidy occur during
gene replacement is not known, but this phenomenon is an
indication that the gene being targeted for replacement is
essential.
In order to test the hypothesis that the GLOI is an essential gene,
an attempt was made to express the gene from an episome by
previous transfection with a plasmid carrying the target gene for
episomal expression and genetic complementation before the
second round of gene replacement. We were successful in
replacing both GLOI loci with two selection markers only in the
presence of an episomal copy of GLOI in the heterozygous
mutant. This shows that the Leishmania donovani GLOI gene is
essential for the survival.
Difference in response to MG of the wild-type and the single
allele knockout mutant further shows that mutants probably have
a significantly reduced rate of metabolism of MG compared to the
wild-type parasites. The heterozygous mutant Ld GLOI :: HYG (+/
h) when complemented with an episomal copy of GLOI was able to
overcome the effect caused by the deletion of one of the allele of
GLOI. It has been implicated that glyoxalase I serves as an
indicator of cell growth status in numerous cells, as its activity is
low in resting cells and high during active cell growth and division
[31,32,7]. The balance between methylglyoxal (the naturally
occurring substrate of glyoxalase I) and glyoxalase I play a decisive
role in the regulation of cell growth [33]. In the present study, it is
possible that the single knock out mutants were unable to detoxify
the cytotoxic effects of endogenous methyglyoxal and its
accumulation induced cell growth retardation [34]. Similar
observations have been made in the GLOI null mutants of
Escherichia coli [35]. Inactivation of the GLOI gene sensitizes cells to
MG. The phenotypic characteristics of the null mutants in the
presence of an episomal copy of GLOI (2/2GLOI+) when
studied were found to be similar to that of GLOI complementation
mutants (data no shown). This data suggests that glyoxalase I may
play an essential role in survival of this pathogenic organism and
the major therapeutic perspective emerging from this study is that
Leishmania GLOI may be further validated as an interesting target
to develop specific chemotherapeutic inhibitors against the
parasite.
Table 2. Comparison of the Glyoxalase I activity of the Wild
type and the mutant strains of glyoxalase I.
Strain
Specific activity6S.D
(nmoles/min/mg)
Wild type (+/+) 486619.8
Ld GLOI :: hyg (+/h) 173631*
Ld GLOI :: neo (+/n) 116.5633*
Ld GLOI hyg :: neo (+/h/n) 109.5613*
Ld GLOI :: hyg GLO I +(+/h -GLOI +) 345628
The Glyoxalase I activity of the wild type and mutant parasites was determined.
Results are mean6S.D. values of three independent experiments. *Significantly
different from the wild type (P,0.001).
doi:10.1371/journal.pone.0006805.t002
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Materials and Methods
Materials
Trypanothione disulphide was purchased from Bachem (Swit-
zerland). [a32P]-dCTP (3000 Ci/mmol) was acquired from
Amersham Biosciences, U.K. All restriction enzymes and DNA
modifying enzymes were obtained from MBI Fermentas (Ger-
many). The pX63-NEO and pX63-HYG, vectors that encompass
the neomycin phosphotransferase (neo) and hygromcin phospho-
transferase genes (hyg) respectively were kindly provided by Dr.
Stephen M. Beverley (Washington University, St. Louis, MO).
Construct pGEM-7zfaNeoa (containing neomycin phosphotrans-
ferase as the selection marker) with GFP was kindly provided by
Dr. Marc Ouellette (University of Laval, Quebec, Canada). The
antibody anti-F1 ATP synthase a-subunit (anti-mouse polyclonal
serum) was kindly provided by Dr. Samit Adhya, Indian Institute
of Chemical biology, Kolkata, India. Probes for neo, phleo and hyg
were obtained by excision of pX63-NEO, pX63-PHLEO and
pX63-HYG with SpeI. The DNA probe used in the present study
included a 426-bp GLOI specific probe. Hygromycin B, Phleomy-
cin and Geneticin (G418) were obtained from Sigma Aldrich
Corp. (St. Louis, MO). Alexa-546 labeled IgG was obtained from
Molecular Probes, Eugene, OR. The other materials used in this
study were of the highest purity and were commercially available.
Cell Culture
L. donovani promastigotes were grown at 22uC in M199 medium
(Sigma St. Louis, MO) supplemented with 100 units/ml penicillin
(Sigma, St. Louis, MO), 100 mg/ml streptomycin (Sigma, St.
Louis, MO) and 10% fetal bovine serum (FBS, Hyclone, U.K.). All
mutants of GLOI gene used in this study were derived from the
wild-type L. donovani strain AG83 (MHOM/IN/1983/AG83)
designated GLOI (+/+) for the purpose of genetic manipulations
described here where GLOI denoted the Glyoxalase I locus and +
specifies the wild-type allele. Promastigotes of mutant parasites
containing functional copies of the neomycin or phleomycin
resistant gene or hygromycin phosphotransferase gene were
routinely maintained in the same medium supplemented with
either 40 mg/ml Geneticin (G418)or 25 mg/ml phleomycin or
200 mg/ml hygromycin respectively. For characterizing the
mutant parasites phenotypically, cells were subcultured without
the selection marker prior to the experiments.
Growth studies
Growth rate experiments were conducted by inoculating
stationary phase parasites at a density of 1 6106 cells/ml in
modified M199 medium with 10% FBS in 25 cm2 flasks without
respective selection drug and cultured at 22uC. Growth rates of
each of the cultures were determined at 24 h intervals by
Neubauer haemocytometer. Growth studies with each individual
cell line were done at least three times and similar results were
obtained consistently.
MTT assay
25 ml of 16 106 parasites/ml of mid log phase promastigotes
were cultured in 96 well tissue culture plates and incubated with
25 ml of varying concentrations of methylglyoxal at 22uC. After
72 h, 20 ml of 5 mg/ml MTT [3-(4, 5- dimethylthiazol-2-yl) -2, 5-
diphenyltetrazolium bromide] (Sigma) dissolved in PBSG (phos-
phate buffered saline with 1% of glucose, pH, 7.4) was added.
Plates were incubated for 6 h at 37uC. Reaction was stopped by
the addition of 50 ml of 50% isopropanol and 10% SDS by gentle
shaking at 37uC for 30 min to 1 h. O.D. was measured
spectrophotometrically at 570 nm [36]. Results are representative
of three independent experiments.
DNA extraction, Southern Blotting and Hybridization
Genomic DNA was extracted from Leishmania using a standard
method [37]. 5 mg of DNA was digested with appropriate
restriction enzymes, separated by 0.8% agarose gel electrophore-
sis, stained with ethidium bromide, transferred onto nylon
membranes (Amersham Pharmacia Biotech) and subjected to
Southern blot analysis. Blots were hybridized with denatured
[a32P] -dCTP labelled DNA probe at 106 c.p.m/ml, which was
labelled by random priming (NEB BlotHKit, New England Biolabs,
Inc.) Membranes were washed, air dried and exposed to an
imaging plate. The image was developed by Phosphoimager (Fuji
FLA25000) using ImageQuant software (Amersham Biosciences).
Construction of GLOI-GFP fusion construct (pGEM-
7zfaNeoa-GLOI-GFP)
The GLOI gene was amplified from the genomic DNA of L.
donovani, using the primers 59- CCCAAGCTTATGCCGTCTC-
GTCGTATG-39 and 59-CCCAAGCTTGGCAGTGCCCTGC-
TCCTT-39 containing a flanking HindIII site (Underlined). The
conditions for PCR were as follows: 94uC for 10 min, then 35
cycles of 94uC for 45 sec, 57uC for 45 sec and 72uC for 1 min.
Final extension was carried out for 10 min at 72uC. The GLOI
PCR product was digested with HindIII and cloned in to the
vector pGEM-7zfaNeoa (containing neomycin phosphotransfer-
ase as the selection marker) with GFP at the carboxy terminal of
the GLOI gene product. The clone was checked for correct
orientation of the insert by restriction enzyme digestion and
confirmed by sequencing. 20 mg of the plasmid, pGEM-7zfa-
Neoa-GLOI-GFP were transfected into the wild type L. donovani.
Methods of electroporation and plating of L. donovani have been
described previously [37]. The transfected cells were maintained in
40 mg/ml of G418. These transfected parasites were used for
localization studies. A control transfection with vector alone,
pGEM-7zfaNeoa-GFP was transfected in to the wild type L.
donovani parasites for comparison.
Localization of GLOI
To detect the site of localization of GLOI in L. donovani, pGEM-
7zfaNeoa-GLOI-GFP transfected promastigotes were used. Fluo-
rescent imaging of the stabilized culture was performed using the
confocal laser scanning microscope (Zeiss LSM 510 META)
equipped with a 636objective, at an excitation wavelength of
488 nm. Briefly 107 promastigotes/ml were pelleted and stained
with MitoTracker Red –CMX-Ros (1 nM) (Molecular Probes,
Eugene, OR) in a fresh media for 10–15 min to locate the
kinetoplast with in the cell. The cells were then washed with
phosphate-buffered saline (PBS) containing 1% fetal bovine serum
(FBS) and resuspended in the same PBS solution with identical
final cell concentration. The promastigotes were then immobilized
on poly (L) lysine coated cover-slips. The cover-slips were
incubated for 1 h at 37uC to allow parasite adherence. The cells
were then treated with methanol/acetone (1:1) for 15 min at
220uC followed by washing with PBS for 5 min. For observing
the fluorescence of the parasites stained with Mitotracker Red –
CMX-Ros the parasites were visualized under confocal laser
scanning microscope at an excitation wavelength of 568 nm.
Immunofluorescence Microscopy
106 promastigotes/ml of the were pelleted and washed twice
with phosphate- buffered saline (PBS) containing 1% fetal bovine
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serum (FBS) and resuspended in the same PBS solution with
identical final cell concentration. The parasites were then
immobilized and fixed as mentioned above and were permeabi-
lised with PBS containing 0.5% Triton X-100 for 5 min, followed
by washing with PBS. Blocking was done using PBS with 1%BSA.
The cells were then incubated in a humidity chamber for 1 h at
room temperature with mouse polyclonal anti-GLOI antibody
(1:100 dilution). After washing with PBS, cells were incubated with
secondary anti-mouse Alexa-546 labeled IgG (Molecular Probes,
Eugene, OR) (diluted 1:2000) for 1 h. The cells were washed with
PBS and incubated with DAPI (0.1 mg/ml) for 15 min at room
temperature. The cover- slips were mounted on the slides and the
parasites were visualized under the confocal laser scanning
microscope at an excitation wavelength of 543 nm for immuno-
flourescence. The parasites stained with DAPI were observed at an
excitation wavelength of 405 nm
Cloning procedures and molecular constructs for the
replacement of GLOI alleles by homologous replacement
Plasmid constructs pX63-HYG, pX63-NEO and pX63-PHLEO
were used for the targeted replacement of GLOI allele in the wild-type
L. donovani strain AG83. To construct drug resistance cassettes to
replace GLOI alleles, 542-bp of 59-flanking region and 1101-bp of 39-
flanking regions of GLOI gene were sub-cloned into the appropriate
sites of the pX63-NEO, pX63-HYG and pX63-PHLEO plasmids.
The 542-bp 59- flanking region was amplified from the AG83
genomic DNA by PCR using a sense primer 59 CCCAAGCT-
TACGGAATAGCGCGACTTG 39 and the antisense primer 59
ACGCGTCGACGAAAGGAGGAAGGGCAGA 39, containing
HindIII and SalI sites (underlined) corresponding to a region ,217
nucleotides upstream from GLOI ORF. The 1101-bp 39 flanking
region was also amplified from the AG83 genomic DNA by PCR
using a sense primer, 59CGCGGATCCCCTGTCTGCCTCGCT-
GAC 39 and the antisense primer, 59 GAAGATCTGCCGGAT-
CAAGCGTTCTC 39 containing BamHI and BglII sites (underlined).
The 39 flank PCR product (,1101-bp) was then sub-cloned into the
BamHI- BglII site of pX63-NEO, pX63-HYG and pX63-PHLEO.
The resulting plasmids were termed pX63-NEO-39F and pX63-
HYG-39F, pX63-PHLEO-39F respectively. The 59 flank PCR
product (,542-bp) was then sub-cloned into the HindIII- SalI site
of pX63-NEO-39F, pX63-HYG-39F and pX63-PHLEO-39F to yield
the three replacement constructs, pX63-NEO-DGLOI, pX63-HYG-
DGLOI and pX63-PHLEO-DGLOI. respectively. The correct
orientation of 59 flank region and 39 flank region within the three
drug resistance cassettes was confirmed by automated sequencing
and restriction mapping.
In order to generate heterozygous mutants of GLOI, five
micrograms of the linearized DNA of the targeting constructs
pX63-NEO-DGLOI or pX63-HYG-DGLOI (digested with HindIII
and BglII) was transfected into mid log phase L. donovani Ag83 wild-
type promastigotes by using standard electroporation conditions for
transfection as reported earlier [37]. Transfection with linearised
pX63-NEO-DGLOI or pX63-HYG-DGLOI into the wild type L.
donovani was done to create the hetrozygote mutants, L. donovani
GLOI :: NEO (+/n) and L. donovani GLOI :: HYG (+/h) respectively.
Transfected Leishmania strains were maintained in liquid medium for
at least 24 h before plating on a drug-containing semi-solid
medium. After selection and stabilization of the liquid culture,
mutant parasites were spread on the plates containing 1% Bacto-
Agar (DIFCO) in M199 media (with 10% FBS) with either G418
(40 mg/ml) or hygromycin (200 mg/ml) as the case may be, to select
for single colonies. The genotype of the L. donovani GLOI :: NEO (+/
n) and L. donovani GLOI :: HYG (+/h) heterozygotes was confirmed
by Southern blot analysis. A heterozygous clone of L. donovani GLOI
:: HYG (+/h) was then subjected to a second round of transfection
with linearised pX63-NEO-DGLOI to obtain null line DGLOI.
These double targeted transfectants, L. donovani GLOI :: HYG :: NEO
(+/h/n) were selected on semi-solid plates containing 1% Bacto-
Agar (DIFCO) in M199 media (with 10% FBS) with both G418
(40 mg/ml) and hygromycin (200 mg/ml). A total of 10 clones of
double targeted transfected line (+/h/n), were picked and screened
by Southern blotting using GLOI ORF as a probe.
Selected clones from L. donovani GLOI :: HYG (+/h) mutants were
also confirmed for the presence of the hygromycin integration cassette
using the hyg specific internal forward primer, P2, 59 -GACTG
TCGGGCGTAC ACA- 39corresponding to a region 905-bp
downstream of the hyg start codon and a reverse primer, P1, 59-
GCAGCGATGGACACCAGAC- 39 corresponding 7to a region
138-bp downstream from the 39flanking region of GLOIORF (Fig. 2).
Selected clones from L. donovani GLOI :: NEO (+/n) mutants were
checked for the presence of the neomycin integration cassette using
the neo specific internal forward primer, P3, 59-GGACCGCTAT-
CAGGACAT- 39corresponding to a region 151-bp downstream of
the neo start codon and a reverse primer, P1, 59- GCAGCGATG-
GACACCAGAC- 39corresponding to a region 138-bp downstream
from the 39flanking region of GLOI ORF (Fig. 2). The gene
replacement of four of the double transfectant clones L. donovani GLOI
:: HYG :: NEO (+/h/n) was further evaluated by polymerase chain
reaction using primers P3 and P1 and also P2 and P1 (Fig. 2).
Genetic complementation of the GLOI heterozygote
mutant
GLOI gene was amplified using the primers 59CCCAAGCT-
TATGCCGTCTCGTCGTATG 39 and 59CCCAAGCTTGG-
CAGTGCCCTGCTCCTT 39 using a flanking HindIII site
(Underlined). The conditions for PCR were as follows: 94uC for
10 min, then 35 cycles of 94uC for 45 sec, 57uC for 45 sec and
72uC for 1 min. Final extension was carried out for 10 min at
72uC. The GLO I PCR product was digested with HindIII and
cloned in the vector pGEM-7zfaNeoa (containing neomycin
phosphotransferase as the selection marker) to create pGEM-
7zfaNeoa-LdGLOI containing the neomycin phosphotransferase
gene. The representative heterozygous mutant, L. donovani GLOI ::
HYG (+/h) were transfected with pGEM-7zfaNeoa -LdGLOI
construct and transfected parasites were then selected in G418
(40 mg/ml) and hygromycin (200 mg/ml) in M199 media contain-
ing 10% FBS. Transfectant lines harboring episomes encompass-
ing the wild-type and single deletion construct (linearized pX63-
HYG-DGLOI) were designated as +/h–GLOI+.
Creating double mutants after episomal
complementation of the GLOI heterozygote mutant
The transfectant cell line harboring the episomes encompassing
the wild-type and single deletion construct (linearized pX63-HYG-
DGLOI) designated as +/h–GLOI+ was transfected with linearized
pX63-PHLEO-DGLOI construct in an an attempt to create double
mutants. These transfectants were selected on semi-solid plates
containing 1% Bacto- Agar (DIFCO) in M199 media (with 10%
FBS) with G418 (40 mg/ml), phleomycin (25 mg/ml) and hygro-
mycin (200 mg/ml). A total of 9 clones were picked and screened
by Southern blotting using GLOI probe. In order to check for the
correct integration of PHLEO based replacement cassette phleo
gene probe was used.
Glyoxalase I activity
16108 promastigotes each from wild type L. donovani, L. donovani
mutant cells were harvested in the late log phase by centrifugation
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at 15006g, at 4uC for 15 min, washed with PBSG, pH-7.4. The
activity of glyoxalase I was assayed spectrophotometrically at room
temperature by measuring the initial rate of formation of S-D-
lactoyl trypanothione at 240 nm as described by Racker with
slight modification [38]. Trypanothione disulphide (1 mM)
(Bachem) was reduced with 3 mM DTT at 60uC for 20 min
before the assay. The resulting reduced trypanothione was used for
GLOI assay. The assay mixture contained, in a final volume of
0.5 ml; 100 mM MOPS buffer, pH 7.2; 400 mM methylglyoxal
(Sigma); 300 mM reduced trypanothione and 20 mM NiCl2 [4].
The assay mixture was incubated for 10 min followed by the
addition of Leishmania cell lysate. Trypanothione hemithioacetal
concentration was calculated by using the published Kd value of
3 mM for the methylglyoxal – glutathione equilibrium [39]. The
value for the De240 nm was taken as 2.86 mM
21 cm21 for the
isomerization of trypanothione hemithioacetal of methylglyoxal
[40]. All assays were performed in triplicate.
Western blot analysis
Late log phase promastigotes (16108) from GLOI-GFP
transfectants were harvested and the resultant cell pellet was
resuspended in lysis buffer (20 mM MOPS, pH 7.2; 1 mM DTT;
2 mM phenylmethylsulfonylfluoride (PMSF); 0.5 mg ml21 each of
leupeptin and aprotinin). The cell pellet was lysed by freeze thaw
and cell supernatants were prepared by centrifugation at 20,0006
g. The supernatant was collected and was used as cytosolic fraction
[41].
For crude mitochondrial fraction mid log phase promastigotes
were harvested and washed with PBSG. The cell pellet was
resuspended in 5 mM Tris, pH- 7.4 and kept at room temperature
for 10 min. Suspension was homogenized using Potter Elvehjem
Homogenizer and centrifuged at 3,500 rpm for 15 min to remove
cellular debris. Supernatant was taken in eppendorf and
centrifuged for 20 min at 12,000 rpm. Pellet was resuspended in
phosphate buffer (5 mM Na-PO4), pH-7.4 at a protein concen-
tration of 10 mg/ml [42]. All centrifugation steps and other
operations were performed at 4uC. 100 mg of protein from each
fraction was fractionated by SDS-polyacrylamide gel electropho-
resis, blotted on to PVDF membrane using electrophoretic transfer
cell (Bio-Rad) and probed with GLOI specific polyclonal antibody
raised in mice (diluted 1:500) [5]. The blots were developed with 3,
39-diaminobenzidine (Sigma).The mitochondrial and cytosolic
fractions were also probed with mitochondrial specific anti –F1
ATP synthase a- subunit (anti–mouse polyclonal serum; diluted
1:250) [43].
DNA Content Analysis
L. donovani promastigotes (1 6107 cells/ml) were harvested by
centrifugation at 20006 g for 5 min at 4uC. Cells were washed
once in phosphate-buffered saline (PBS; 0.01 M phosphate buffer,
2.7 M KCl, 0.137 M NaCl, pH-7.4). The cells were then fixed by
incubation in 70% methanol/30% PBS for 1 h at 4uC. Prior to
analysis fixed cells were harvested by centrifugation at 10006 g,
for 10 min at 4uC, washed in PBS and then resuspended in 1 ml
PBS with RNAse A (10 mg/ml) and incubated at 37uC for 20 min.
Following this propidium iodide (50 mg/ml) was added. Samples
were then analyzed using a flow cytometer (FACS, Beckton
Dickinson). For each sample at least 10,000 cells were analyzed.
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